 Tamara Timic Stamenic
Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Calcium Channels, T-Type | 9 | 2025 | 104 | 4.540 |
Why?
| | Hypnotics and Sedatives | 5 | 2025 | 224 | 2.070 |
Why?
| | Thalamus | 4 | 2025 | 127 | 2.000 |
Why?
| | Pregnanolone | 3 | 2025 | 34 | 1.920 |
Why?
| | Hypnosis | 2 | 2025 | 12 | 1.800 |
Why?
| | Neurons | 7 | 2025 | 1647 | 1.470 |
Why?
| | Pregnanediones | 2 | 2026 | 12 | 1.140 |
Why?
| | Intralaminar Thalamic Nuclei | 2 | 2019 | 22 | 1.120 |
Why?
| | Receptors, GABA-A | 9 | 2016 | 137 | 1.110 |
Why?
| | Isoflurane | 5 | 2025 | 41 | 1.030 |
Why?
| | Conditioning, Classical | 1 | 2025 | 120 | 0.820 |
Why?
| | Membrane Potentials | 3 | 2022 | 278 | 0.820 |
Why?
| | Maze Learning | 8 | 2016 | 106 | 0.790 |
Why?
| | Anesthetics, General | 1 | 2022 | 14 | 0.710 |
Why?
| | Fear | 1 | 2025 | 367 | 0.690 |
Why?
| | Diazepam | 7 | 2016 | 33 | 0.670 |
Why?
| | Electrophysiological Phenomena | 4 | 2025 | 59 | 0.660 |
Why?
| | Androstanols | 1 | 2020 | 30 | 0.630 |
Why?
| | Mice, Inbred C57BL | 9 | 2026 | 5989 | 0.610 |
Why?
| | Dizocilpine Maleate | 2 | 2018 | 24 | 0.590 |
Why?
| | Nitriles | 1 | 2020 | 205 | 0.580 |
Why?
| | Action Potentials | 3 | 2020 | 502 | 0.560 |
Why?
| | Amphetamine | 3 | 2016 | 38 | 0.540 |
Why?
| | GABA-A Receptor Agonists | 4 | 2016 | 17 | 0.540 |
Why?
| | Ventral Tegmental Area | 1 | 2018 | 62 | 0.510 |
Why?
| | Animals | 26 | 2026 | 38141 | 0.490 |
Why?
| | Memory Disorders | 2 | 2015 | 198 | 0.490 |
Why?
| | Mice, Knockout | 7 | 2025 | 3125 | 0.490 |
Why?
| | Anesthesia | 1 | 2019 | 258 | 0.470 |
Why?
| | Hyperkinesis | 1 | 2015 | 16 | 0.450 |
Why?
| | Reflex, Righting | 2 | 2025 | 15 | 0.450 |
Why?
| | Rats, Wistar | 12 | 2016 | 449 | 0.440 |
Why?
| | Adenosine Triphosphate | 1 | 2018 | 503 | 0.440 |
Why?
| | Electroencephalography | 4 | 2025 | 563 | 0.420 |
Why?
| | Mice | 10 | 2026 | 18338 | 0.420 |
Why?
| | Anesthetics, Inhalation | 3 | 2026 | 52 | 0.410 |
Why?
| | GABA Modulators | 2 | 2012 | 11 | 0.400 |
Why?
| | Midazolam | 1 | 2012 | 73 | 0.370 |
Why?
| | Benzodiazepines | 4 | 2015 | 168 | 0.350 |
Why?
| | Memory | 1 | 2012 | 297 | 0.310 |
Why?
| | Brain | 2 | 2020 | 2944 | 0.310 |
Why?
| | Sex Characteristics | 2 | 2025 | 779 | 0.300 |
Why?
| | Male | 24 | 2026 | 72817 | 0.300 |
Why?
| | Rats | 13 | 2019 | 5581 | 0.280 |
Why?
| | Patch-Clamp Techniques | 2 | 2025 | 289 | 0.240 |
Why?
| | Imidazoles | 2 | 2016 | 246 | 0.240 |
Why?
| | Methyl Ethers | 1 | 2026 | 19 | 0.240 |
Why?
| | Calcium Channels, R-Type | 1 | 2025 | 5 | 0.220 |
Why?
| | Behavior, Animal | 4 | 2021 | 526 | 0.220 |
Why?
| | Carbolines | 3 | 2013 | 35 | 0.210 |
Why?
| | Somatosensory Cortex | 1 | 2025 | 43 | 0.210 |
Why?
| | Gene Silencing | 1 | 2025 | 202 | 0.210 |
Why?
| | RNA, Small Interfering | 1 | 2025 | 632 | 0.190 |
Why?
| | Rats, Sprague-Dawley | 2 | 2018 | 2526 | 0.180 |
Why?
| | Synapses | 1 | 2026 | 438 | 0.180 |
Why?
| | Motor Activity | 5 | 2018 | 723 | 0.170 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2014 | 188 | 0.170 |
Why?
| | Calcium Channel Blockers | 2 | 2020 | 166 | 0.160 |
Why?
| | Autism Spectrum Disorder | 1 | 2026 | 420 | 0.160 |
Why?
| | Ventral Thalamic Nuclei | 1 | 2019 | 5 | 0.150 |
Why?
| | Nitrous Oxide | 1 | 2019 | 35 | 0.140 |
Why?
| | Models, Animal | 1 | 2020 | 395 | 0.140 |
Why?
| | Rats, Transgenic | 1 | 2018 | 19 | 0.140 |
Why?
| | Protein Isoforms | 1 | 2019 | 396 | 0.140 |
Why?
| | Tissue Culture Techniques | 1 | 2018 | 82 | 0.130 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2018 | 107 | 0.130 |
Why?
| | Cytosol | 1 | 2018 | 214 | 0.130 |
Why?
| | Synaptic Transmission | 1 | 2019 | 292 | 0.120 |
Why?
| | Green Fluorescent Proteins | 1 | 2018 | 407 | 0.120 |
Why?
| | Female | 8 | 2025 | 78763 | 0.120 |
Why?
| | GABA-A Receptor Antagonists | 2 | 2012 | 19 | 0.120 |
Why?
| | Anxiety | 2 | 2014 | 1127 | 0.110 |
Why?
| | Risperidone | 1 | 2015 | 29 | 0.110 |
Why?
| | Dopamine | 1 | 2018 | 295 | 0.110 |
Why?
| | Emulsions | 1 | 2015 | 59 | 0.110 |
Why?
| | Anti-Anxiety Agents | 2 | 2013 | 47 | 0.110 |
Why?
| | Schizophrenia | 2 | 2015 | 444 | 0.100 |
Why?
| | Maternal Exposure | 1 | 2015 | 188 | 0.100 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2015 | 229 | 0.100 |
Why?
| | Muscarinic Antagonists | 1 | 2012 | 30 | 0.090 |
Why?
| | Spatial Behavior | 1 | 2012 | 24 | 0.090 |
Why?
| | Muscle Relaxation | 1 | 2012 | 28 | 0.090 |
Why?
| | Lipopolysaccharides | 1 | 2015 | 855 | 0.090 |
Why?
| | Ataxia | 1 | 2012 | 69 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2013 | 2030 | 0.090 |
Why?
| | Drug Stability | 2 | 2016 | 169 | 0.090 |
Why?
| | Xenopus laevis | 2 | 2016 | 105 | 0.080 |
Why?
| | Cognition Disorders | 1 | 2015 | 541 | 0.080 |
Why?
| | Hand Strength | 2 | 2016 | 144 | 0.080 |
Why?
| | Seizures | 1 | 2014 | 482 | 0.080 |
Why?
| | Nanoparticles | 1 | 2015 | 519 | 0.070 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2015 | 651 | 0.070 |
Why?
| | Cognition | 1 | 2015 | 1268 | 0.060 |
Why?
| | Locomotion | 1 | 2016 | 102 | 0.060 |
Why?
| | Epilepsy, Absence | 1 | 2025 | 12 | 0.060 |
Why?
| | Caspase 3 | 1 | 2026 | 234 | 0.050 |
Why?
| | HEK293 Cells | 1 | 2016 | 743 | 0.050 |
Why?
| | Calcium Channels, L-Type | 1 | 2025 | 118 | 0.050 |
Why?
| | Social Behavior | 1 | 2026 | 288 | 0.050 |
Why?
| | Animals, Newborn | 1 | 2026 | 890 | 0.050 |
Why?
| | Kinetics | 1 | 2016 | 1605 | 0.050 |
Why?
| | Flumazenil | 2 | 2012 | 8 | 0.050 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2026 | 452 | 0.050 |
Why?
| | Adjuvants, Anesthesia | 1 | 2021 | 13 | 0.040 |
Why?
| | Isomerism | 1 | 2021 | 57 | 0.040 |
Why?
| | Ion Transport | 1 | 2020 | 62 | 0.040 |
Why?
| | Hippocampus | 1 | 2026 | 969 | 0.040 |
Why?
| | Benzamides | 1 | 2020 | 224 | 0.040 |
Why?
| | Piperidines | 1 | 2020 | 221 | 0.040 |
Why?
| | Inhibitory Postsynaptic Potentials | 1 | 2019 | 47 | 0.040 |
Why?
| | Excitatory Postsynaptic Potentials | 1 | 2019 | 119 | 0.030 |
Why?
| | Emulsifying Agents | 1 | 2015 | 3 | 0.030 |
Why?
| | Lecithins | 1 | 2015 | 5 | 0.030 |
Why?
| | Stearic Acids | 1 | 2015 | 15 | 0.030 |
Why?
| | Technology, Pharmaceutical | 1 | 2015 | 30 | 0.030 |
Why?
| | Poloxamer | 1 | 2015 | 13 | 0.030 |
Why?
| | Polysorbates | 1 | 2015 | 42 | 0.030 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2015 | 112 | 0.030 |
Why?
| | Solubility | 1 | 2015 | 237 | 0.030 |
Why?
| | Particle Size | 1 | 2015 | 402 | 0.030 |
Why?
| | Protein Subunits | 1 | 2014 | 228 | 0.020 |
Why?
| | Drug Inverse Agonism | 1 | 2012 | 3 | 0.020 |
Why?
| | Humans | 2 | 2022 | 145491 | 0.020 |
Why?
| | Autistic Disorder | 1 | 2015 | 217 | 0.020 |
Why?
| | Rotarod Performance Test | 1 | 2012 | 15 | 0.020 |
Why?
| | Benzodiazepinones | 1 | 2012 | 18 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 382 | 0.020 |
Why?
| | Drug Tolerance | 1 | 2012 | 99 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2015 | 772 | 0.020 |
Why?
| | Reaction Time | 1 | 2012 | 438 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2015 | 1212 | 0.020 |
Why?
| | Anticonvulsants | 1 | 2013 | 246 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2015 | 652 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 2110 | 0.020 |
Why?
| | Muscle Strength | 1 | 2012 | 332 | 0.020 |
Why?
| | Pyridines | 1 | 2012 | 607 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2015 | 4559 | 0.010 |
Why?
| | Pregnancy | 1 | 2015 | 7197 | 0.010 |
Why?
|
|
Timic Stamenic's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|